knowledge -WSS

knowledge

author：fashion 2025-09-06 02:13:51 - browse：27

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Eli Lilly expects to double planned employment in Boston center

focus

leisure time

WSS

Impact of Dobbs ruling felt at reproductive medicine meeting

FDA gives detailed accounting of AI

CDC panel: People 65 and older should get a Covid spring booster shot

Color Health wants to make cancer screenings convenient

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Medicare reduced heart disease by changing how it pays doctors

knowledge

knowledge

hotspot

New air purifier tech could be key to improving indoor air quality

STAT Madness 2024: Meet the contenders

Jerome Adams on the need for new antivirals for Covid

How climate

What does generative AI mean for health care? We asked experts

Solve the antibiotic resistance crisis with preventive drugs

Medicare proposal to cover medical devices draws a mixed reaction

Solve the antibiotic resistance crisis with preventive drugs

As demand for Covid shots wanes, Moderna seeks its next success

HHS leader on health, climate change and biopharma emissions

hotspot

FDA gives detailed accounting of AI

FDA gives detailed accounting of AI

HHS leader on health, climate change and biopharma emissions

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

UnitedHealth’s board chair also owns a personal investment firm

Change Healthcare cyberattack shows risk of industry consolidation

focus

leisure time

Wikipedia

leisure time